Synlogic has entered a platform collaboration with biotech company Ginkgo Bioworks to support...
- FDA greenlight for esketamine sheds light on ketamine’s potential
- Diabetes Week: investigating the immune basis of type 1 diabetes
- AstraZeneca’s Calquence shows superiority to chemotherapy in CLL
- Researchers discover new drug target in tuberculosis
- FDA approves first drug for episodic cluster headaches
Synlogic and Ginkgo Bioworks to develop biotic drugs
Synlogic has entered a platform collaboration with biotech company Ginkgo Bioworks to support its synthetic bionic medicines pipeline.
FDA greenlight for esketamine sheds light on ketamine’s potential
In March, the FDA approved Janssen Pharmaceuticals’ depression drug esketamine, a form of ketamine for use as a treatment for depression. Billed as the most exciting antidepressant in decades, the drug has an entirely new mechanism of action. So what does esketamine offer, and why is the FDA so sure the benefits outweigh the risks?
Genmab and Janssen Biotech to develop CD38 antibody
Genmab has signed a global licence and option agreement with Janssen Biotech for the development and commercialisation of a human CD38 monoclonal antibody (mAb).
Stroke: a growing burden across eight major markets to 2027
The burden of AIS is expected to increase in the 8MM over the next decade due in part to population ageing, and increased prevalence of stroke-associated risk factors.
Deciphera licenses cancer drug ripretinib to Zai Lab in China
US-based Deciphera Pharmaceuticals has signed an exclusive licence agreement with biopharmaceutical company Zai Lab to develop and commercialise cancer therapeutic ripretinib in Greater China.
Boehringer expands PROTAC drugs partnership with Dundee University
Boehringer Ingelheim has extended a collaboration with the University of Dundee in Scotland for the development of proteolysis targeting chimera (PROTAC) based drugs to treat cancer.
Exscientia and GT Apeiron form AI drug discovery alliance
Exscientia has entered a multi-target partnership with China-based GT Apeiron Therapeutics.
The microbiome in IBD: multiomics analysis may help clarify an elusive mechanism of action
One of the key takeaways from the study was that the gut microbiome was far more unstable longitudinally in people with IBD than in people without IBD.
Elemental Impurity Analysis in Pharmaceuticals and Implementation of ICH Q3D
Elemental impurities have been a hot topic since 2009 when the International Conference of Harmonisation (ICH) commenced work on a new standard to provide a global policy to limit these impurities in drug products and ingredients.
How Virtualisation Can Help Electronic Data Retention
One of the most discussed topics currently affecting good manufacturing practices (GMP) laboratories, data integrity involves conforming to fundamental elements of quality: attributable, legible, cotemporaneous, original, and accurate (ALCOA). Of these, legibility presents a particularly tough challenge.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.